Inj rituximab, hyaluronidase
Products billed under this code include Rituxan Hycela.
Payment limit per 10 mg, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Rituxan Hycela.
Payment limit per 10 mg, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Rituxan Hycela | Genentech, Inc. | 50242-0108-01 | 140 | $5,077.10 |
| Rituxan Hycela | Genentech, Inc. | 50242-0109-01 | 160 | $5,802.40 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $36.265 | −$0.124 | 10 mg | Inj rituximab, hyaluronidase | v1, posted September 17, 2026 |
| 3Q26 | $36.389 | +$0.107 | 10 mg | Inj rituximab, hyaluronidase | v1, posted September 15, 2026 |
| 2Q26 | $36.282 | −$0.592 | 10 mg | Inj rituximab, hyaluronidase | v1, posted September 15, 2026 |
| 1Q26 | $36.874 | +$0.181 | 10 mg | Inj rituximab, hyaluronidase | v1, posted September 15, 2026 |
| 4Q25 | $36.693 | −$0.269 | 10 mg | Inj rituximab, hyaluronidase | v1, posted September 8, 2026 |
| 3Q25 | $36.962 | −$0.564 | 10 mg | Inj rituximab, hyaluronidase | v1, posted March 10, 2026 |
| 2Q25 | $37.526 | +$0.95 | 10 mg | Inj rituximab, hyaluronidase | v1, posted March 10, 2026 |
| 1Q25 | $36.576 | −$0.366 | 10 mg | Inj rituximab, hyaluronidase | v1, posted December 19, 2025 |
| 4Q24 | $36.942 | +$0.415 | 10 mg | Inj rituximab, hyaluronidase | v1, posted June 11, 2025 |
| 3Q24 | $36.527 | −$0.712 | 10 mg | Inj rituximab, hyaluronidase | v1, posted June 11, 2025 |
| 2Q24 | $37.239 | −$0.166 | 10 mg | Inj rituximab, hyaluronidase | v1, posted March 11, 2025 |
| 1Q24 | $37.405 | +$0.272 | 10 mg | Inj rituximab, hyaluronidase | v1, posted December 19, 2024 |
| 4Q23 | $37.133 | −$0.325 | 10 mg | Inj rituximab, hyaluronidase | v1, posted October 10, 2024 |
| 3Q23 | $37.458 | −$0.034 | 10 mg | Inj rituximab, hyaluronidase | v1, posted June 5, 2024 |
| 2Q23 | $37.492 | +$0.322 | 10 mg | Inj rituximab, hyaluronidase | v1, posted February 23, 2024 |
| 1Q23 | $37.17 | −$0.707 | 10 mg | Inj rituximab, hyaluronidase | v1, posted December 6, 2023 |
| 4Q22 | $37.877 | −$0.024 | 10 mg | Inj rituximab, hyaluronidase | v1, posted June 22, 2023 |
| 3Q22 | $37.901 | −$0.058 | 10 mg | Inj rituximab, hyaluronidase | v1, posted June 9, 2023 |
| 2Q22 | $37.959 | −$0.251 | 10 mg | Inj rituximab, hyaluronidase | v1, posted December 14, 2022 |
| 1Q22 | $38.21 | +$0.27 | 10 mg | Inj rituximab, hyaluronidase | v1, posted June 8, 2022 |
| 4Q21 | $37.94 | −$0.329 | 10 mg | Inj rituximab, hyaluronidase | v1, posted June 2, 2022 |
| 3Q21 | $38.269 | −$0.528 | 10 mg | Inj rituximab, hyaluronidase | v1, posted June 2, 2022 |
| 2Q21 | $38.797 | −$1.104 | 10 mg | Inj rituximab, hyaluronidase | v1, posted March 1, 2022 |
| 1Q21 | $39.901 | – | 10 mg | Inj rituximab, hyaluronidase | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.